Cleared Traditional

K992041 - RELISA ANA SCREENING TEST SYSTEM

K992041 is the FDA 510(k) clearance for RELISA ANA SCREENING TEST SYSTEM by Immuno Concepts, Inc.. It is a Class 2 Immunology device (product code LJM) cleared through the Traditional 510(k) pathway after a 36-day FDA review.

K992041 · Immuno Concepts, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 1999
Decision
36d
Days
Class 2
Risk

K992041 is an FDA 510(k) clearance for the RELISA ANA SCREENING TEST SYSTEM, MODEL 7096-11. Classified as Antinuclear Antibody (enzyme-labeled), Antigen, Controls (product code LJM), Class II - Special Controls.

Submitted by Immuno Concepts, Inc. (Dallas, US). The FDA issued a Cleared decision on July 23, 1999 after a review of 36 days - a notably fast clearance cycle.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5100 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Immuno Concepts, Inc. devices

Submission Details

510(k) Number K992041 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 17, 1999
Decision Date July 23, 1999
Days to Decision 36 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
68d faster than avg
Panel avg: 104d · This submission: 36d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code LJM Antinuclear Antibody (enzyme-labeled), Antigen, Controls
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5100
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - LJM Antinuclear Antibody (enzyme-labeled), Antigen, Controls

All 38
Devices cleared under the same product code (LJM) and FDA review panel - the closest regulatory comparables to K992041.
QUANTA LITE CENTROMERE (CENP-A & CENP-B) ELISA
K003959 · Inova Diagnostics, Inc. · Jan 2001
THE APTUS (AUTOMATED) APPLICATION OF THE TG IGG ELISA TEST SYSTEM. AN ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) FOR THE
K000879 · Zeus Scientific, Inc. · May 2000
THE APTUS (AUTOMATED APPLICATION OF THE TPO IGG ELISA TEST SYSTEM. AN ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) FOR THE
K000880 · Zeus Scientific, Inc. · May 2000
THE APTUS (AUTOMATED) APPLICATION OF THE ANA SCREEN ELISA TEST SYSTEM. AN ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) FOR.
K983378 · Zeus Scientific, Inc. · Nov 1998
ELIAS ANA-HEP-2
K964385 · Elias U.S.A., Inc. · Mar 1997
HY-TEC/MANUAL AUTOIMMUNE KIT FOR HISTONE
K962450 · Hycor Biomedical, Inc. · Nov 1996